🇺🇸 FDA
Pipeline program

KEYTRUDA 25 mg/mL concentrate for solution for infusion, Olaparib, Olaparib

POINT

Phase 2 small_molecule active

Quick answer

KEYTRUDA 25 mg/mL concentrate for solution for infusion, Olaparib, Olaparib for Adult patients affected by recurrent/metastatic, platinum resistant nasopharyngeal cancer is a Phase 2 program (small_molecule) at Fondazione Telethon ETS with 1 ClinicalTrials.gov record(s).

Program details

Company
Fondazione Telethon ETS
Indication
Adult patients affected by recurrent/metastatic, platinum resistant nasopharyngeal cancer
Phase
Phase 2
Modality
small_molecule
Status
active

Clinical trials